Vivos Therapeutics, Inc. (VVOS)

Market Cap	2.87M -87.9%
Revenue (ttm)	20.90M +45.2%
Net Income	-25.46M
EPS	-1.83
Shares Out	20.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,624,108
Open	0.1348
Previous Close	0.1340
Day's Range	0.1276 - 0.1500
52-Week Range	0.1276 - 3.2790
Beta	6.07
Analysts	Buy
Price Target	2.12 (+1,384.59%)
Est. Earnings	Nov 18, 2026

About VVOS

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its a...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 270
• Stock Exchange: Nasdaq
• Ticker Symbol: VVOS
• Website: https://www.vivos.com

Financial Performance

In 2025, Vivos Therapeutics's revenue was $17.44 million, an increase of 16.05% compared to the previous year's $15.03 million. Losses were -$21.17 million, 90.1% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for VVOS stock is "Buy." The 12-month stock price target is $2.12, which is an increase of 1,384.59% from the latest price.

Price Target

$2.12

(1,384.59% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error